Alliancebernstein L.P. Annexon, Inc. Transaction History

Alliancebernstein L.P.

$287 Billion
Q3 2024

A detailed history of Alliancebernstein L.P. transactions in Annexon, Inc. stock. As of the latest transaction made, Alliancebernstein L.P. holds 127,360 shares of ANNX stock, worth $653,356. This represents 0.0% of its overall portfolio holdings.

Number of Shares

127,360

Previous 146,450 13.04%

Holding current value

$653,356

Previous $717,000 5.02%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$4.49 - $7.2 $85,714 - $137,448	-19,090 Reduced 13.04%	127,360 $753,000
Q2 2024 Aug 14, 2024	BUY	$4.33 - $6.79 $458,243 - $718,585	105,830 Added 260.54%	146,450 $717,000
Q2 2023 Aug 15, 2023	BUY	$2.1 - $6.37 $85,302 - $258,749	40,620 New	40,620 $142,000
Q2 2022 Aug 15, 2022	SELL	$2.11 - $4.06 $5.24 Million - $10.1 Million	-2,483,650 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$2.73 - $11.94 $1.07 Million - $4.7 Million	393,295 Added 18.81%	2,483,650 $6.78 Million
Q4 2021 Feb 14, 2022	BUY	$11.49 - $22.0 $4.29 Million - $8.21 Million	373,074 Added 21.72%	2,090,355 $24 Million
Q3 2021 Nov 10, 2021	BUY	$16.35 - $23.4 $1.96 Million - $2.8 Million	119,758 Added 7.5%	1,717,281 $32 Million
Q2 2021 Jul 30, 2021	BUY	$17.81 - $27.48 $2.68 Million - $4.13 Million	150,368 Added 10.39%	1,597,523 $36 Million
Q1 2021 May 06, 2021	BUY	$22.0 - $35.01 $6.86 Million - $10.9 Million	311,677 Added 27.45%	1,447,155 $40.3 Million
Q4 2020 Feb 08, 2021	BUY	$20.81 - $30.55 $3.25 Million - $4.77 Million	156,056 Added 15.93%	1,135,478 $28.4 Million
Q3 2020 Nov 12, 2020	BUY	$17.5 - $30.23 $17.1 Million - $29.6 Million	979,422 New	979,422 $29.6 Million

Others Institutions Holding ANNX

# of Institutions

146

Shares Held

102M

Call Options Held

178K

Put Options Held

159K

View Full List

About Annexon, Inc.

Ticker ANNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,617,700
Market Cap $244M
Description
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated n...

More about ANNX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

News

Stay updated on Alliancebernstein L.P. with notifications on news.

Account

Alliancebernstein L.P. Annexon, Inc. Transaction History